EvaluatePharma - Watson Pharmaceuticals - Worldwide

Watson Pharmaceuticals

All Financial Data in US $ (mln)

Worldwide

Overview

Company News

Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference
Watson Pharmaceuticals (September 08, 2010)

Watson Confirms Combigan(R) Patent Challenge
Watson Pharmaceuticals (September 07, 2010)

Watson's Generic Yasmin(R) Receives FDA Approval
Watson Pharmaceuticals (September 07, 2010)

U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014
Eli Lilly (September 01, 2010)

Watson to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Watson Pharmaceuticals (September 01, 2010)

Watson Plans Q4 2010 ella(R) (ulipristal acetate) Emergency Contraceptive Launch
Watson Pharmaceuticals (August 13, 2010)

FDA Grants Approval of Ella® for Emergency Contraception
HRA Pharma (August 13, 2010)

Watson Q2 Net Revenue Climbs 29 Percent to $875 Million
Watson Pharmaceuticals (August 05, 2010)

Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
Watson Pharmaceuticals (August 04, 2010)

Watson Promotes Robert Stewart to Executive Vice President, Global Operations Generic R&D Incorporated Into Global Operations Function
Watson Pharmaceuticals (August 03, 2010)

Displaying 10 out of a possible 749 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Watson Pharmaceuticals (WPI), a California based specialty & generic pharmaceutical company.
Listed or Private Company	Listed
Company Classification	Specialty; Generic
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
7/23/2010	23 Jul: A Wall Street Journal report states that the US FTC has refuted allegations made by Watson that it acted improperly during an investigation into Watson's business dealings with Cephalon and has also asserted that the company's CEO, Paul Bisaro, has impeded the agency's investigation.	5,187	-4.4%	-237

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Ferrlecit	sodium ferric gluconate	Anti-anaemics	132²	133³	+0%
2	Hydrocodone / Acetaminophen	acetaminophen & hydrocodone bitartrate	Narcotic analgesics	120	125	+4%
3	Bupropion	bupropion hydrochloride	Anti-depressants	47⁴	85⁵	+82%

Note: Shaded Cells⁶

RX Sales Chart

Watson Pharmaceuticals	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals	1,734	1,755	+1%

Therapy Area Focus in 2008

Watson Pharmaceuticals
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	166
Cardiovascular	99
Central Nervous System	468
Dermatology	25
Endocrine	19
Gastro-Intestinal	62
Genito-Urinary	429
Musculoskeletal	95
Oncology & Immunomodulators	44
Respiratory	10
Systemic Anti-Infectives	44
Other Rx & OTC Pharma	340

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Watson Pharmaceuticals ⁷	254

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Generic Lipitor highlights divisive Canadian healthcare market (May 20, 2010)

Court gives new hope for bans on pay for delay deals (April 30, 2010)

Watson Concerta court ruling should make J&J sit up and pay attention (April 27, 2010)

Can Takeda prolong Actos' life? (March 11, 2010)

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XX XXXX, XXXXXXXXX® XXXXXXXXX XXX XXXXXXXXXXXXX X% XX XXX XXX XXXXXXXX XXX XX% XX XXX XXXXX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXXXXXXXX XXXXXXX XXXXXXXX $XX.X XXXXXXX XX $XX.X XXXXXXX XXX XXX XXXXXX XXXXXXX XXXX XXX XXXXXXXX $XX.X XXXXXXX XX $XX.X XXXXXXX XXX XXX XXXX XXXX XXXX, XXXXXXXXXX XXX XXXX XXXXXXXXXXXX XX XXXXXXXXX(X) XXXXXXX XXXXXX XX XX XXXXXXXX XX, XXXX

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXX XXXXXX XXXX XXX XXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX, XXXXXXXXX XXXXXXXXXXXXX XXXXXXXX-XXXXXXX XXXXXXX XXX XX, XXXXXXXX XXXXXXXXXXX XXXXX, XXXXXXXXX XXXXXXX XXX XXXXX XX XX XXXXXXXXXXX $XX.X XXXXXXX XX XXX XXXXXXXX XX XXXXXXX XXXXXXX XXXXX XXXXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
......XXX XXXXXX XXXXXXX XXXX XXXXXX XX XXXXXXXXX XXXXXXXXXXXXX XXX XX XXXXXXXX-XXXXXXX XXXXXXX......

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX X:
XXXXXX XXXX, XX XXXXXXXX XXX XXXXXXX XXXXXXX XXXX XXXX XXX XXXXXX XX XX XXXXXXX XXXXXXXX. XXX XXXXXXXX XX XXXX XXXXXXXX XXXXXXXXX XXXXXXXXXXXXX XX XXXXX XXXXXXX, XX XXXX-XXXXXXXXXX XXXXXXXX XX XXXXXXXX XXXX.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.